Cargando…
Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?
Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life‐span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each...
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585618/ https://www.ncbi.nlm.nih.gov/pubmed/29901216 http://dx.doi.org/10.1002/cpt.1121 |
| _version_ | 1783428735010078720 |
|---|---|
| author | Eichler, Hans‐Georg Bedlington, Nicola Boudes, Mathieu Bouvy, Jacoline C. Broekmans, André W. Cerreta, Francesca Faulkner, Stuart D. Forda, Susan R. Joos, Angelika Le Cam, Yann Mayer, Mark H. Pirard, Vinciane Corriol‐Rohou, Solange |
| author_facet | Eichler, Hans‐Georg Bedlington, Nicola Boudes, Mathieu Bouvy, Jacoline C. Broekmans, André W. Cerreta, Francesca Faulkner, Stuart D. Forda, Susan R. Joos, Angelika Le Cam, Yann Mayer, Mark H. Pirard, Vinciane Corriol‐Rohou, Solange |
| author_sort | Eichler, Hans‐Georg |
| collection | PubMed |
| description | Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life‐span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each milestone of the product life‐span. These considerations are of relevance for regulatory and access pathways that strive to address the “evidence vs. access” conundrum. |
| format | Online Article Text |
| id | pubmed-6585618 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65856182019-06-27 Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? Eichler, Hans‐Georg Bedlington, Nicola Boudes, Mathieu Bouvy, Jacoline C. Broekmans, André W. Cerreta, Francesca Faulkner, Stuart D. Forda, Susan R. Joos, Angelika Le Cam, Yann Mayer, Mark H. Pirard, Vinciane Corriol‐Rohou, Solange Clin Pharmacol Ther Reviews Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life‐span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each milestone of the product life‐span. These considerations are of relevance for regulatory and access pathways that strive to address the “evidence vs. access” conundrum. John Wiley and Sons Inc. 2018-09-11 2019-05 /pmc/articles/PMC6585618/ /pubmed/29901216 http://dx.doi.org/10.1002/cpt.1121 Text en © 2018 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Reviews Eichler, Hans‐Georg Bedlington, Nicola Boudes, Mathieu Bouvy, Jacoline C. Broekmans, André W. Cerreta, Francesca Faulkner, Stuart D. Forda, Susan R. Joos, Angelika Le Cam, Yann Mayer, Mark H. Pirard, Vinciane Corriol‐Rohou, Solange Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? |
| title | Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? |
| title_full | Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? |
| title_fullStr | Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? |
| title_full_unstemmed | Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? |
| title_short | Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? |
| title_sort | medicines adaptive pathways to patients: why, when, and how to engage? |
| topic | Reviews |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585618/ https://www.ncbi.nlm.nih.gov/pubmed/29901216 http://dx.doi.org/10.1002/cpt.1121 |
| work_keys_str_mv | AT eichlerhansgeorg medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT bedlingtonnicola medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT boudesmathieu medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT bouvyjacolinec medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT broekmansandrew medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT cerretafrancesca medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT faulknerstuartd medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT fordasusanr medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT joosangelika medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT lecamyann medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT mayermarkh medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT pirardvinciane medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT corriolrohousolange medicinesadaptivepathwaystopatientswhywhenandhowtoengage AT medicinesadaptivepathwaystopatientswhywhenandhowtoengage |